Tonix Pharma Stock’s Retail Chatter Explodes

Tonix Pharma Stock’s Retail Chatter Explodes After FDA Nod For New Drug Application
Tonix Pharmaceuticals was the most active symbol on Stocktwits before the bell on Wednesday as shares of the clinical-stage biopharmaceutical company surged over 35% in premarket after witnessing a significant decline on Tuesday.
Tonix Pharmaceuticals Announces FDA Acceptance of the New Drug Application (NDA) for TNX-102 SL for Fibromyalgia
FDA is expected to assign a Prescription Drug User Fee Act (PDUFA) target action date and announce whether Priority Review has been granted in the Day 74 Letter TNX-102 SL is a non-opioid, centrally acting analgesic,
Tonix Pharmaceuticals Gets FDA Review of Fibromyalgia Drug
Tonix Pharmaceuticals Holding said the Food and Drug Administration has accepted its application seeking approval of its TNX-102 SL product candidate for the chronic pain condition fibromyalgia.
FDA accepts Tonix’s NDA for non-opioid fibromyalgia drug TNX-102 SL
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for TNX-102 SL, a non-opioid, centrally acting analgesic designed for fibromyalgia management.
Tonix Pharma’s TNX-102 SL Nears FDA Approval Milestone
Tonix Pharma ( (TNXP) ) has provided an announcement.
Tonix Pharmaceuticals (NASDAQ:TNXP) Now Covered by Analysts at StockNews.com
Equities researchers at StockNews.com assumed coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP – Get Free Report) in a report released on Sunday. The firm set a “sell” rating on the stock. Tonix Pharmaceuticals Stock Performance Shares of NASDAQ TNXP opened at $0.
What's Going On With Tonix Pharmaceuticals Stock Today?
Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) shares are trading lower Tuesday after initially jumping after the company ...
Tonix Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Highlights
Submitted New Drug Application (NDA) to FDA for TNX-102 SL for fibromyalgia based on two statistically significant Phase 3 ...
bovnews2d
What’s Driving Tonix Pharmaceuticals Holding Corp (TNXP) Stock’s 70.33% Surge Over the Past Month?
Tonix Pharmaceuticals Holding Corp (TNXP) stock saw a modest uptick, ending the day at $0.24 which represents a slight increase of $0.01 or 4.35% from the prior close of $0.23. The stock opened at $0.
Monthly Prescribing Reference22h
FDA to Review Sublingual Cyclobenzaprine for Fibromyalgia Management
The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for TNX-102 SL (cyclobenzaprine HCL sublingual tablets) for the management of fibromyalgia.
Tonix Pharmaceuticals announces FDA acceptance of NDA for TNX-102 SL
Tonix Pharmaceuticals (TNXP) announced that the U.S. Food and Drug Administration, FDA, has accepted the filing of its New Drug Application, ...